AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2858187 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 504
Study 2858187 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 504
Study 2858187 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 504
Study 2858187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 504
Study 31683159 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% height starting position
Number of subjects: 34
Study 31683159 — intervention group
Group type: EXPERIMENTAL
Intervention: 36" starting position
Number of subjects: 34
Study 31683159 — intervention group
Group type: EXPERIMENTAL
Intervention: bi-acromial distance starting position
Number of subjects: 34
Study 31683159 — intervention group
Group type: EXPERIMENTAL
Intervention: bi-acromial distance with reach to 36" starting position
Number of subjects: 34
Study 31293262 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract (compomer)
Number of subjects: 30
Study 31293262 — intervention group
Group type: EXPERIMENTAL
Intervention: Freedom (compomer)
Number of subjects: 30
Study 31293262 — intervention group
Group type: EXPERIMENTAL
Intervention: Equia (high‐viscosity glass ionomer cement)
Number of subjects: 30
Study 31293262 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji IX (resin‐modified glass ionomer cement)
Number of subjects: 30
Study 31293262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac Molar (traditional glass ionomer cement)
Number of subjects: 30
Study 31293262 — intervention group
Group type: EXPERIMENTAL
Intervention: Voco (traditional glass ionomer cement)
Number of subjects: 30
Study 31293262 — intervention group
Group type: COMPARATOR
Intervention: Fluoride release analysis
Number of subjects: 30
Study 28604089 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mL of 2% lidocaine with epinephrine 1:100,000
Number of subjects: 160
Study 28604089 — intervention group
Group type: COMPARATOR
Intervention: 0.9 mL of 4% articaine with epinephrine 1:100,000
Number of subjects: 160
Study 28604089 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (lidocaine and articaine)
Number of subjects: 160
Study 26493267 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin intercalated with Gefitinib (PCG) - P 175 mg/m², C AUC 5 on day 1, G 250 mg orally on days 2-15 for four cycles followed by G 250 mg orally until progressive disease.
Number of subjects: 90
Study 26493267 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and Carboplatin alone (PC) - same dosing schedule for four cycles only.
Number of subjects: 90
Study 26493267 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin intercalated with Gefitinib (PCG)
Number of subjects: 90
Study 26493267 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and Carboplatin alone (PC)
Number of subjects: 90
Study 22427403 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 30
Study 22427403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21170558 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5-cm mesial resection
Number of subjects: 207
Study 21170558 — intervention group
Group type: COMPARATOR
Intervention: 3.5-cm mesial resection
Number of subjects: 207
Study 19491536 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 4400
Study 17336941 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg/day
Number of subjects: 92
Study 17336941 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone 0 mg/day (placebo)
Number of subjects: 92
Study 17336941 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone 50 mg/day
Number of subjects: 92
Study 14763917 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (significant weight loss)
Number of subjects: 96
Study 14763917 — intervention group
Group type: COMPARATOR
Intervention: Diet (small weight loss)
Number of subjects: 96
Study 14763917 — intervention group
Group type: COMPARATOR
Intervention: Obese patients (no intervention)
Number of subjects: 96
Study 14763917 — intervention group
Group type: COMPARATOR
Intervention: Obese patients with T2DM
Number of subjects: 96
Study 11248662 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 800 mg daily by mouth
Number of subjects: 677
Study 11248662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 677
Study 8996143 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 75 mg/m2 every 3 weeks plus Cyclophosphamide 750 mg/m2 (CC group, n = 22)
Number of subjects: 46
Study 8996143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m2 every 3 weeks plus Paclitaxel 175 mg/m2 over a 3-hour infusion (CP group, n = 24)
Number of subjects: 46
Study 8996143 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus Cyclophosphamide (CC group)
Number of subjects: 46
Study 8996143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus Paclitaxel (CP group)
Number of subjects: 46
Study 8490639 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental healthy weight regulation curriculum
Number of subjects: 967
Study 8490639 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control classes
Number of subjects: 967
Study 3449047 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-time care in the special nursing home unit
Number of subjects: 0
Study 3449047 — intervention group
Group type: COMPARATOR
Intervention: Community care (waiting list with periodic respite care)
Number of subjects: 0
Study 29642382 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index dietary intervention during pregnancy
Number of subjects: 60
Study 29642382 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific dietary advice)
Number of subjects: 60
Study 27194175 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual clinic
Number of subjects: 208
Study 27194175 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 208
Study 24864486 — intervention group
Group type: EXPERIMENTAL
Intervention: sylvinite speleoclimatotherapy (10 sessions, 60 min each) in addition to conventional pharmacotherapy
Number of subjects: 23
Study 24864486 — intervention group
Group type: COMPARATOR
Intervention: traditional medicamental therapy alone
Number of subjects: 23
Study 23402084 — intervention group
Group type: COMPARATOR
Intervention: TAC-Placebo (PLAC)
Number of subjects: 35
Study 23402084 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC-Short-term (2 mo) low-dose steroid (STER)
Number of subjects: 35
Study 23402084 — intervention group
Group type: COMPARATOR
Intervention: Composite endpoint
Number of subjects: 35
Study 23402084 — intervention group
Group type: EXPERIMENTAL
Intervention: Rejection treatment
Number of subjects: 35
Study 20377585 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA + C/B
Number of subjects: 730
Study 20377585 — intervention group
Group type: COMPARATOR
Intervention: ADA + vehicle
Number of subjects: 730
Study 18534177 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluoride dentifrice without post-brushing rinse
Number of subjects: 5
Study 18534177 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoride dentifrice followed by a water rinse
Number of subjects: 5
Study 18534177 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluoride dentifrice with post-brushing rinse
Number of subjects: 5
Study 16248241 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Qingwen Baidu Decoction (MQBD) in addition to conventional therapy (corticosteroid, anti-viral, anti-bacterial, symptomatic and supporting therapy)
Number of subjects: 34
Study 16248241 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (corticosteroid, anti-viral, anti-bacterial, symptomatic and supporting therapy)
Number of subjects: 34
Study 12503692 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol (50 microg b.d.; SM50)
Number of subjects: 20
Study 12503692 — intervention group
Group type: EXPERIMENTAL
Intervention: fluticasone propionate (250 microg b.d.; FP250)
Number of subjects: 20
Study 12503692 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 9794674 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 200 microg
Number of subjects: 178
Study 9794674 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal misoprostol 50 microg
Number of subjects: 178
Study 9794674 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 178
Study 7636057 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide (10 mg/body square meters)
Number of subjects: 40
Study 7636057 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution)
Number of subjects: 40
Study 2696034 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment arm 1
Number of subjects: 762
Study 2696034 — intervention group
Group type: COMPARATOR
Intervention: Treatment arm 2
Number of subjects: 762
Study 335867 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimazosin (300 and 450 mg daily)
Number of subjects: 16
Study 335867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 335867 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimazosin
Number of subjects: 16
Study 31272711 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation thrusts of perceived least intensity
Number of subjects: 13
Study 31272711 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation thrusts of perceived appropriate intensity
Number of subjects: 13
Study 31272711 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation thrusts of perceived greatest intensity
Number of subjects: 13
Study 31272711 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pressure models
Number of subjects: 13
Study 31272711 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrust duration and time to peak acceleration
Number of subjects: 13
Study 28699044 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA1 phototherapy
Number of subjects: 64
Study 28699044 — intervention group
Group type: COMPARATOR
Intervention: Narrowband UVB (NB‐UVB) therapy
Number of subjects: 64
Study 25500679 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA (propofol-remifentanil total i.v. anaesthesia)
Number of subjects: 80
Study 25500679 — intervention group
Group type: COMPARATOR
Intervention: DES (desflurane anaesthesia)
Number of subjects: 80
Study 25500679 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA
Number of subjects: 80
Study 25500679 — intervention group
Group type: COMPARATOR
Intervention: DES
Number of subjects: 80
Study 23827983 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii-balance board intervention (6 weeks, M=8h, 22 min, SD=53 min)
Number of subjects: 29
Study 23827983 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study 20495919 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose capecitabine (CCB 1) 1,250 mg/m² p.o. twice daily for 2 weeks
Number of subjects: 7
Study 20495919 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-intensified capecitabine (CCB 2) 1,750 mg/m² p.o. twice daily for 1 week
Number of subjects: 7
Study 19335850 — intervention group
Group type: EXPERIMENTAL
Intervention: RV apical pacing
Number of subjects: 800
Study 19335850 — intervention group
Group type: COMPARATOR
Intervention: RV septal pacing
Number of subjects: 800
Study 16400045 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulating ten 3‐min bouts of exercise (totaling 30 minutes)
Number of subjects: 10
Study 16400045 — intervention group
Group type: EXPERIMENTAL
Intervention: One continuous 30‐min bout of exercise
Number of subjects: 10
Study 16400045 — intervention group
Group type: COMPARATOR
Intervention: Control trial (no exercise)
Number of subjects: 10
Study 15385204 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular sonotherapy (IST)
Number of subjects: 403
Study 15385204 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 403
Study 11296045 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tramadol
Number of subjects: 64
Study 11296045 — intervention group
Group type: COMPARATOR
Intervention: Oral diclofenac
Number of subjects: 64
Study 9370898 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 25 mg/m2
Number of subjects: 26
Study 9370898 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone 15 mg/m2
Number of subjects: 26
Study 9370898 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Number of subjects: 26
Study 1555625 — intervention group
Group type: EXPERIMENTAL
Intervention: SR-verapamil 360 mg o.d.
Number of subjects: 19
Study 1555625 — intervention group
Group type: COMPARATOR
Intervention: nifedipine 20 mg t.d.s.
Number of subjects: 19
Study 3890279 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin
Number of subjects: 32
Study 3890279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 30676426 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional dysphagia therapy
Number of subjects: 18
Study 30676426 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 18
Study 30676426 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (rTMS + traditional dysphagia therapy)
Number of subjects: 18
Study 28807635 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg (n=183)
Number of subjects: 455
Study 28807635 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg with laser (n=180)
Number of subjects: 455
Study 28807635 — intervention group
Group type: COMPARATOR
Intervention: Laser (with optional ranibizumab 0.5 mg after month 6; n=92)
Number of subjects: 455
Study 28807635 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg with laser
Number of subjects: 455
Study 28807635 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg monotherapy
Number of subjects: 455
Study 28807635 — intervention group
Group type: COMPARATOR
Intervention: Laser (monotherapy and combined with ranibizumab from month 6)
Number of subjects: 455
Study 26318715 — intervention group
Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine (neonatal schedule)
Number of subjects: 95
Study 26318715 — intervention group
Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine (infant schedule)
Number of subjects: 95
Study 26318715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 26318715 — intervention group
Group type: EXPERIMENTAL
Intervention: RV3-BB vaccine and Placebo
Number of subjects: 95
Study 23099622 — intervention group
Group type: EXPERIMENTAL
Intervention: Marcy repair
Number of subjects: 91
Study 23099622 — intervention group
Group type: COMPARATOR
Intervention: Prolene Hernia System repair
Number of subjects: 91
Study 20461382 — intervention group
Group type: EXPERIMENTAL
Intervention: PX-12 (54 or 128 mg/m²) administered by 3-hour IV infusion daily for 5 days every 21 days
Number of subjects: 17
Study 20461382 — intervention group
Group type: EXPERIMENTAL
Intervention: PX-12 (128 mg/m²)
Number of subjects: 17
Study 20461382 — intervention group
Group type: EXPERIMENTAL
Intervention: PX-12 (54 mg/m²)
Number of subjects: 17
Study 18752112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT)
Number of subjects: 432
Study 17153908 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-modality therapy
Number of subjects: 0
Study 17153908 — intervention group
Group type: COMPARATOR
Intervention: Standard of care for locally advanced cervical cancer
Number of subjects: 0
Study 12843799 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (100 MIU subcutaneously)
Number of subjects: 98
Study 12843799 — intervention group
Group type: COMPARATOR
Intervention: Granulocyte-macrophage colony-stimulating factor (500 microg subcutaneously)
Number of subjects: 98
Study 11007235 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial kit for antitissue transglutaminase antibodies (INOVA Diagnostics, Inc.)
Number of subjects: 79
Study 11007235 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiendomysial antibody
Number of subjects: 79
Study 11007235 — intervention group
Group type: COMPARATOR
Intervention: Antitissue transglutaminase antibodies (blind determination)
Number of subjects: 79
Study 8770996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 0
Study 8770996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (treatment duration > or = 24 months)
Number of subjects: 0
Study 8770996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (GFR < or = 50 ml/min/1.73 m2)
Number of subjects: 0
Study 8770996 — intervention group
Group type: EXPERIMENTAL
Intervention: FK‐506
Number of subjects: 0
Study 8770996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine to FK‐506 conversion
Number of subjects: 0
Study 8770996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine and FK‐506
Number of subjects: 0
Study 1478285 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional isolated perfusion as adjuvant treatment
Number of subjects: 0
Study 1478285 — intervention group
Group type: COMPARATOR
Intervention: Local excision only
Number of subjects: 0
Study 6494011 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphonuclear leukocyte transfusions
Number of subjects: 13
Study 6494011 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 13
Study 3531255 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued UVB phototherapy after initial clearing
Number of subjects: 0
Study 3531255 — intervention group
Group type: COMPARATOR
Intervention: Discontinued UVB phototherapy within 3 weeks after initial clearing
Number of subjects: 0
Study 31453489 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy group (n=52)
Number of subjects: 104
Study 31453489 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=52)
Number of subjects: 104
Study 28318860 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Number of subjects: 79
Study 28318860 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia Iliaca Compartment Block (FICB)
Number of subjects: 79
Study 28318860 — intervention group
Group type: COMPARATOR
Intervention: Retrospective Control Group
Number of subjects: 79
Study 26250966 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional Risk Index (NRI)
Number of subjects: 160
Study 26250966 — intervention group
Group type: COMPARATOR
Intervention: ESCAPE mortality model
Number of subjects: 160
Study 23915885 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) training
Number of subjects: 6771
Study 23915885 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced communication training
Number of subjects: 6771
Study 23915885 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (CRP and enhanced communication)
Number of subjects: 6771
Study 23915885 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6771
Study 21934290 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam + alfentanil
Number of subjects: 115
Study 21934290 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 115
Study 18069027 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS with high-intensity stimulation at segmental and extrasegmental sites
Number of subjects: 208
Study 18069027 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 208
Study 17070355 — intervention group
Group type: EXPERIMENTAL
Intervention: ProstaLund Feedback Treatment (PLFT)
Number of subjects: 120
Study 17070355 — intervention group
Group type: COMPARATOR
Intervention: Surgery (TURP/prostate enucleation)
Number of subjects: 120
Study 14763350 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 8
Study 10883872 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX mouthwash
Number of subjects: 40
Study 10883872 — intervention group
Group type: COMPARATOR
Intervention: CHX spray
Number of subjects: 40
Study 8926511 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental clinical teaching method using computer-assisted instruction (CAI) and a collaboration model during initial clinical experiences.
Number of subjects: 83
Study 8926511 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 83
Study 1443446 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalinized depot grass allergoid (cumulative pre-seasonal dosage of 46,050 PNU)
Number of subjects: 19
Study 1443446 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalinized depot grass allergoid
Number of subjects: 19
Study 1443446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 6534451 — intervention group
Group type: EXPERIMENTAL
Intervention: Excretory cystography
Number of subjects: 100
Study 6534451 — intervention group
Group type: EXPERIMENTAL
Intervention: Excretory cystography for papillary tumours >= 0.5 cm
Number of subjects: 100
Study 6534451 — intervention group
Group type: EXPERIMENTAL
Intervention: Excretory cystography for tumours < 0.5 cm
Number of subjects: 100
Study 29925930 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study 29925930 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rituximab with therapy targeting CD4+ T cells
Number of subjects: 0
Study 27890801 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided paclitaxel injection (PTX) plus standard of care (SOC)
Number of subjects: 137
Study 27890801 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 137
Study 25720672 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 capsules once weekly for 8 weeks
Number of subjects: 112
Study 25720672 — intervention group
Group type: COMPARATOR
Intervention: Starch capsules (placebo) once weekly for 8 weeks
Number of subjects: 112
Study 23490393 — intervention group
Group type: EXPERIMENTAL
Intervention: Narlaprevir followed by PEG‐IFN/RBV
Number of subjects: 40
Study 21819556 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 17.5 mg weekly
Number of subjects: 31
Study 21819556 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA) 2.5 mg/kg daily
Number of subjects: 31
Study 19183127 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day
Number of subjects: 18
Study 19183127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18